$URGN News

UroGen Pharma (NASDAQ:URGN) Combines High Growth Momentum with a Breakout Setup

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma to Present at Upcoming Investor Conferences

Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet

IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies

UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline

UroGen Pharma Announces Strategic Option And Research License Agreement And Related Equity Investment Agreement With IntraGel Therapeutics

UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC

UroGen Pharma Submits NDA To FDA For Its Investigational Drug UGN-103 For Intravesical Solution

Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice

UroGen (URGN) Q2 2026 Earnings Call Transcript

UroGen Pharma (URGN) Earnings Put Its Fair Value Debate Back In Focus

Why UroGen Pharma (URGN) Is Up 22.8% After Q2 2026 Revenue Nearly Tripled And Losses Narrowed

Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $58

HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $75

UroGen Pharma Ltd (URGN) (Q2 2026) Earnings Call Highlights: Cysview Revenue Surges 73% as Net ...

Urogen Pharma Q2 Earnings Call Highlights

TD Cowen Maintains Buy on UroGen Pharma, Raises Price Target to $60

UroGen Pharma Ltd. (URGN) Q2 2026 Earnings Call Transcript

Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates